The Non-Malignant Channel is supported with funding from Agios (Gold).
The Thalassemia Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCAT 2024 | The history of improving outcomes in thalassemia and the importance of the multidisciplinary team
Malcolm Walker, MD, FRCP, University College London, London, UK, discusses the evolution of treatments for thalassemia, a condition that was once universally fatal in childhood. Several key advancements, such as the development of MRI techniques to measure iron overload in the heart, have led to significant reductions in patient mortality rates and extended life expectancy. Prof. Walker also highlights the importance of collaboration between hematologists and specialists in fields like cardiology to ensure the best possible outcomes for patients. This interview took place at the 19th Annual Scientific Conference of the Academy for Sickle Cell and Thalassaemia (ASCAT 2024) in London, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
